Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Zhu W, Libal NL, Casper A, Bodhankar S, Offner H, Alkayed NJ.

Transl Stroke Res. 2014 Oct;5(5):612-7. doi: 10.1007/s12975-014-0348-8. Epub 2014 Jun 24.

2.

Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke.

Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, Alkayed NJ.

Transl Stroke Res. 2015 Feb;6(1):60-8. doi: 10.1007/s12975-014-0373-7. Epub 2014 Oct 2.

3.

Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice.

Zhu W, Dotson AL, Libal NL, Lapato AS, Bodhankar S, Offner H, Alkayed NJ.

Neuroscience. 2015 Mar 12;288:112-9. doi: 10.1016/j.neuroscience.2014.12.037. Epub 2014 Dec 31.

4.

Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke.

Pan J, Palmateer J, Schallert T, Hart M, Pandya A, Vandenbark AA, Offner H, Hurn PD.

Transl Stroke Res. 2014 Oct;5(5):577-85. doi: 10.1007/s12975-014-0345-y. Epub 2014 May 18.

5.

Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.

Murakami K, Suzuki M, Suzuki N, Hamajo K, Tsukamoto T, Shimojo M.

Brain Res. 2013 Aug 14;1526:84-93. doi: 10.1016/j.brainres.2013.06.014. Epub 2013 Jun 20.

PMID:
23791950
6.

Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.

Berny-Lang MA, Hurst S, Tucker EI, Pelc LA, Wang RK, Hurn PD, Di Cera E, McCarty OJ, Gruber A.

Stroke. 2011 Jun;42(6):1736-41. doi: 10.1161/STROKEAHA.110.603811. Epub 2011 Apr 21.

7.

Recombinant T cell receptor ligand treats experimental stroke.

Subramanian S, Zhang B, Kosaka Y, Burrows GG, Grafe MR, Vandenbark AA, Hurn PD, Offner H.

Stroke. 2009 Jul;40(7):2539-45. doi: 10.1161/STROKEAHA.108.543991. Epub 2009 May 14.

9.

Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.

El Amki M, Lerouet D, Coqueran B, Curis E, Orset C, Vivien D, Plotkine M, Marchand-Leroux C, Margaill I.

Exp Neurol. 2012 Dec;238(2):138-44. doi: 10.1016/j.expneurol.2012.08.005. Epub 2012 Aug 19.

PMID:
22921458
10.

Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.

Romanos E, Planas AM, Amaro S, Chamorro A.

J Cereb Blood Flow Metab. 2007 Jan;27(1):14-20. Epub 2006 Apr 5.

PMID:
16596120
11.

Neuroprotective effect of masitinib in rats with postischemic stroke.

Kocic I, Kowianski P, Rusiecka I, Lietzau G, Mansfield C, Moussy A, Hermine O, Dubreuil P.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):79-86. doi: 10.1007/s00210-014-1061-6. Epub 2014 Oct 26.

12.

Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.

You YP.

J Stroke Cerebrovasc Dis. 2016 Apr;25(4):990-7. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.014. Epub 2016 Feb 3.

PMID:
26851971
13.

Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.

Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, Hozeska A, Zhang C, Li L, Morris D, Zhang RL, Lu M, Chopp M.

Circulation. 2005 Nov 29;112(22):3486-94.

14.
16.

Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.

Haddad M, Beray-Berthat V, Coqueran B, Plotkine M, Marchand-Leroux C, Margaill I.

Fundam Clin Pharmacol. 2013 Aug;27(4):393-401. doi: 10.1111/j.1472-8206.2012.01036.x. Epub 2012 Mar 21.

PMID:
22436003
17.
18.

Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice.

Dziennis S, Mader S, Akiyoshi K, Ren X, Ayala P, Burrows GG, Vandenbark AA, Herson PS, Hurn PD, Offner HA.

Metab Brain Dis. 2011 Jun;26(2):123-33. doi: 10.1007/s11011-011-9241-2. Epub 2011 Apr 7.

19.

Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.

Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV.

Stroke. 2013 Dec;44(12):3529-36. doi: 10.1161/STROKEAHA.113.003350. Epub 2013 Oct 24.

20.

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC.

Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25.

PMID:
18462720

Supplemental Content

Support Center